Compare Quest Diagnostics Inc (DGX) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs abrdn Physical Palladium Shares ETF — how do they compare? Quest Diagnostics Inc trades at $237.6 (market cap $26.21B), while abrdn Physical Palladium Shares ETF trades at $24.92. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while abrdn Physical Palladium Shares ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| DGX | PALL | |
|---|---|---|
Market Cap | $26.21B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $238.50 | $37.18 |
52-Week Low | $173.49 | $19.96 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
PALL (Aberdeen Physical Palladium Shares ETF) trades at $24.87, down 0.96% over 24 hours. Technical indicators show a bullish overall signal with moving averages supporting upside momentum, though oscillators are neutral. Recent news highlights palladium's underperformance relative to other precious metals, with some analysts viewing current price weakness as a buying opportunity. The ETF provides exposure to physical palladium, which has declined 47% from January 2026 highs.
The outlook for PALL hinges on palladium's supply-demand dynamics and industrial demand recovery. Investment opportunity exists if palladium prices rebound from current depressed levels, supported by supply risks and potential catch-up trade. Key risks include continued commodity price volatility, Federal Reserve policy uncertainty, and weaker industrial demand affecting palladium's fundamental drivers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
